NEVIRAPINE SYNERGISTICALLY INHIBITS HIV-1 REPLICATION IN COMBINATION WITH ZIDOVUDINE, INTERFERON OR CD4 IMMUNOADHESIN

被引:20
作者
KOUP, RA
BREWSTER, F
GROB, P
SULLIVAN, JL
机构
[1] UNIV MASSACHUSETTS,SCH MED,DEPT PEDIAT,WORCESTER,MA 01605
[2] UNIV MASSACHUSETTS,SCH MED,PROGRAM MOLEC MED,WORCESTER,MA 01605
[3] BOEHRINGER INGELHEIM PHARMACEUT INC,RIDGEFIELD,CT
关键词
HIV-1; ANTIVIRAL; COMBINATION CHEMOTHERAPY;
D O I
10.1097/00002030-199309000-00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine whether synergistic inhibition of HIV-1 replication would result from the in vitro use of nevirapine in combination with zidovudine, interferon (IFN)-alpha 2C, and CD4 immunoadhesin. Design and methods: The non-nucleoside reverse transcriptase inhibitor nevirapine (formerly BI-RG-587) was tested in combination with the other antiretroviral agents. Assays were performed on stimulated peripheral blood lymphocytes infected with HIV-1. Virus replication was assessed by the release of viral p24 antigen into culture supernatants. The median-effect principle was used to assess for synergistic interactions of the combined agents. Results: Zidovudine, IFN-alpha 2C and CD4 immunoadhesin, when used in combination with nevirapine, synergistically inhibited HIV-1 replication in human peripheral blood lymphocytes compared with each agent used alone. Some analyses were also consistent with additive effects, but antagonism was not noted. Conclusion: These in vitro findings provide a scientific basis for future trials with similar drug combinations.
引用
收藏
页码:1181 / 1184
页数:4
相关论文
共 35 条
[1]   RESISTANCE OF PRIMARY ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TO SOLUBLE CD4 IS INDEPENDENT OF CD4-RGP120 BINDING-AFFINITY [J].
ASHKENAZI, A ;
SMITH, DH ;
MARSTERS, SA ;
RIDDLE, L ;
GREGORY, TJ ;
HO, DD ;
CAPON, DJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (16) :7056-7060
[2]   DESIGNING CD4 IMMUNOADHESINS FOR AIDS THERAPY [J].
CAPON, DJ ;
CHAMOW, SM ;
MORDENTI, J ;
MARSTERS, SA ;
GREGORY, T ;
MITSUYA, H ;
BYRN, RA ;
LUCAS, C ;
WURM, FM ;
GROOPMAN, JE ;
BRODER, S ;
SMITH, DH .
NATURE, 1989, 337 (6207) :525-531
[3]   PHARMACOKINETICS OF NEVIRAPINE - INITIAL SINGLE-RISING-DOSE STUDY IN HUMANS [J].
CHEESEMAN, SH ;
HATTOX, SE ;
MCLAUGHLIN, MM ;
KOUP, RA ;
ANDREWS, C ;
BOVA, CA ;
PAV, JW ;
ROY, TP ;
SULLIVAN, JL ;
KEIRNS, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (02) :178-182
[4]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[5]   USE OF EVOLUTIONARY LIMITATIONS OF HIV-1 MULTIDRUG RESISTANCE TO OPTIMIZE THERAPY [J].
CHOW, YK ;
HIRSCH, MS ;
MERRILL, DP ;
BECHTEL, LJ ;
ERON, JJ ;
KAPLAN, JC ;
DAQUILA, RT .
NATURE, 1993, 361 (6413) :650-654
[6]   HIGH-CONCENTRATIONS OF RECOMBINANT SOLUBLE CD4 ARE REQUIRED TO NEUTRALIZE PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES [J].
DAAR, ES ;
LI, XL ;
MOUDGIL, T ;
HO, DD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (17) :6574-6578
[7]   RELATIVE RESISTANCE OF PRIMARY HIV-1 ISOLATES TO NEUTRALIZATION BY SOLUBLE CD4 [J].
DAAR, ES ;
HO, DD .
AMERICAN JOURNAL OF MEDICINE, 1991, 90 :S22-S26
[8]   A SOLUBLE FORM OF CD4 (T4) PROTEIN INHIBITS AIDS VIRUS-INFECTION [J].
DEEN, KC ;
MCDOUGAL, JS ;
INACKER, R ;
FOLENAWASSERMAN, G ;
ARTHOS, J ;
ROSENBERG, J ;
MADDON, PJ ;
AXEL, R ;
SWEET, RW .
NATURE, 1988, 331 (6151) :82-84
[9]   HIV INFECTION IS BLOCKED INVITRO BY RECOMBINANT SOLUBLE CD4 [J].
FISHER, RA ;
BERTONIS, JM ;
MEIER, W ;
JOHNSON, VA ;
COSTOPOULOS, DS ;
LIU, T ;
TIZARD, R ;
WALKER, BD ;
HIRSCH, MS ;
SCHOOLEY, RT ;
FLAVELL, RA .
NATURE, 1988, 331 (6151) :76-78
[10]   INVITRO SELECTION OF VARIANTS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RESISTANT TO 3'-AZIDO-3'-DEOXYTHYMIDINE AND 2',3'-DIDEOXYINOSINE [J].
GAO, Q ;
GU, ZX ;
PARNIAK, MA ;
LI, XG ;
WAINBERG, MA .
JOURNAL OF VIROLOGY, 1992, 66 (01) :12-19